Business Wire

SOLAR-PROMOTION-GMBH

8.5.2024 17:40:34 CEST | Business Wire | Press release

Share
The smarter E AWARD 2024: Finalists Present Pioneering Solutions for a Renewable 24/7 Energy Supply

The energy industry is undergoing a radical transformation. Renewable sources of energy have become increasingly profitable in recent years and are now the most economically viable solution for generating electricity. Deployment is accelerating and the technologies are becoming increasingly sophisticated. This has put renewables in the fast lane. Visionary companies are contributing to this development with modern technologies, ideas and concepts. The best and most innovative developments have been nominated for The smarter E AWARD 2024. The prize is awarded in five categories: Photovoltaics, Energy Storage, E-Mobility, Smart Integrated Energy and Outstanding Projects. The winners will be honored on the eve of The smarter E Europe on June 18 at 6:15pm at the International Congress Center München (ICM). Europe’s largest alliance of exhibitions for the energy industry unites four exhibitions (Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe) and will take place at Messe München from June 19–21.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508604806/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The finalists for The smarter E AWARD 2024 have been announced in the five categories. (© Solar Promotion GmbH)

Intelligent, innovative, interdisciplinary – as Europe’s largest alliance of exhibitions for the energy industry, The smarter E Europe highlights key topics for a renewable 24/7 energy supply. The focus will be on solar energy, storage technologies, electromobility and grid and energy management. The smarter E AWARD is presented every year as part of this exhibition. The innovation prize recognizes companies and their products that are actively shaping tomorrow’s energy world. This year's finalists showcase clear trends – from artificial intelligence and digital twins to software-as-a-service solutions to higher performance and efficiency. These companies are the finalists of The smarter E AWARD 2024.

The finalists of the Photovoltaics category

  • Aiko Energy (China)
  • ArcelorMittal Construction (France)
  • Euronergy (Netherlands)
  • Institute for Solar Energy Research ISFH + Aerial PV Inspection (Germany)
  • NexWafe (Germany)
  • PVcase (Lithuania)
  • Shenzhen Hopewind Electric (China)
  • SMA Solar Technology (Germany)
  • Solar Materials (Germany)
  • WAVELABS Solar Metrology Systems (Germany)

The finalists of the Energy Storage category

  • Contemporary Amperex Technology Co., Limited (CATL) (China)
  • Cubenergy (China)
  • Enphase Energy (USA)
  • ESS Tech (USA)
  • HagerEnergy (Germany)
  • Jackery Technology (USA)
  • Pfannenberg Europe (Germany)
  • Sigenergy Technology Co., Ltd. (China)
  • sonnen (Germany)
  • Trina Storage (China)

The finalists of the E-Mobility category

  • Autel Europe (Germany)
  • Designwerk Technologies (Switzerland)
  • EcoG (Germany)
  • Huawei Digital Power (China)
  • Road (Netherlands)
  • SolarPaint by Apollo Power (Israel)
  • Vector Informatik (Germany)
  • XCharge Europe (Germany)

Finalists of the Smart Integrated Energy category

  • CyberGrid (Germany)
  • Delfos – Intelligence Asset Management (Spain)
  • dvlp.energy (Germany)
  • Entrix (Germany)
  • Off-Grid Europe (Germany)
  • PIONIERKRAFT (Germany)
  • SolarEdge (Israel)
  • suena (Germany)
  • The Mobility House (Germany)

Finalists in the Outstanding Projects category

  • 3SUN (Italy)
  • Beijing HyperStrong Technology (China)
  • Boreal Light (Germany)
  • CALB Group (China)
  • Huawei Digital Power (China)
  • IO-Dynamics (Germany)
  • LONGi Solar Technology (China)
  • MaxSolar (Germany)
  • Red Sea Global (Saudi Arabia)
  • Siemens (Germany)

For more information, please visit:
www.TheSmarterE-award.com

The smarter E Europe

“Accelerating Integrated Energy Solutions“ – this is the motto of The smarter E Europe. Europe’s largest alliance of exhibitions for the energy industry puts the spotlight on cross-industry solutions for a renewable 24/7 energy supply covering electricity, heat and transport. The smarter E Europe unites four exhibitions and will take place from June 19–21, 2024 at Messe München.

More information: www.TheSmarterE.de

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508604806/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye